NASDAQ$RVPH
Reviva Pharmaceuticals Holdi · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reviva reported full year 2022 financial results and provided recent business highlights.
Reviva Pharmaceuticals reported a net loss of $24.3 million for the year ended December 31, 2022, with cash and cash equivalents totaling $18.5 million. The company believes its cash will be sufficient to fund operating plans through the third quarter of 2023. Topline data for the pivotal Phase 3 trial evaluating brilaroxazine for schizophrenia remains on track for mid-2023.
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023.
- The company completed the majority of non-clinical and clinical prelaunch measures for brilaroxazine New Drug Application (NDA) submission.
- Positive clinical drug-drug interaction data reinforces a differentiated pharmacological and safety profile for brilaroxazine.
- Over 50% of approximately 400 patients have been enrolled in the pivotal Phase 3 RECOVER study evaluating brilaroxazine for schizophrenia.
Headline financials
Revenue & EPS history
Reviva · Revenue · Quarterly
$0
Forward guidance
Reviva anticipates topline data for the pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia in mid-2023 and may initiate Phase 2a studies in bipolar disorder, major depressive disorder, and attention deficit hyperactive disorder in the second half 2023, subject to the receipt of additional financing.
Tailwinds
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023
- May initiate Phase 2a studies in bipolar disorder, major depressive disorder, and attention deficit hyperactive disorder in second half 2023, subject to the receipt of additional financing
- Pursue partnership opportunities for the development of our pipeline
- Evaluate grant and other non-dilutive financing opportunities for our product candidates from Federal and State Healthcare Agencies and Foundations
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
-1.2%
Avg return
Earnings day
-0.5%
Avg return
5 days after
+16.7%
Avg return
30 days after
39%
11 / 28 earnings
Positive
+15.8%
Q2 2025
Best reaction
-22.9%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +9.6% | +13.7% | +94.3% | |
| Q3 2025 | -7.3% | -7.9% | +23.0% | |
| Q2 2025 | +15.8% | +11.4% | -5.1% | |
| Q1 2025 | +4.9% | +31.6% | -8.1% | |
| Q4 2024 | +15.0% | +16.0% | +17.1% | |
| Q3 2024 | -9.6% | +0.8% | +108.8% | |
| Q1 2024 | +0.6% | -1.8% | -11.8% | |
| Q4 2023 | -9.8% | -18.2% | -53.7% | |
| Q3 2023 | -17.2% | -33.6% | -37.1% | |
| Q2 2023 | +3.4% | +0.0% | +28.8% | |
| Q1 2023 | +5.4% | -0.5% | -15.6% | |
| Q4 2022 | -10.1% | -5.2% | +47.0% | |
| Q3 2022 | -22.9% | -9.5% | -21.6% | |
| Q2 2022 | +2.8% | +4.9% | +208.5% | |
| Q1 2022 | +15.3% | +17.1% | -20.4% | |
| Q4 2021 | +0.0% | -3.3% | +21.1% | |
| Q3 2021 | -1.3% | -10.3% | -11.4% | |
| Q2 2021 | -6.0% | -4.9% | +18.3% | |
| Q1 2021 | -0.2% | +12.2% | -1.2% | |
| Q4 2020 | -22.3% | -22.6% | -46.5% | |
| Q3 2020 | -0.7% | — | — | |
| Q2 2020 | +0.0% | — | — | |
| Q1 2020 | +0.1% | — | — | |
| Q4 2019 | +0.0% | — | — | |
| Q3 2019 | +0.0% | — | — | |
| Q2 2019 | +0.4% | — | — | |
| Q1 2018 | -0.1% | — | — | |
| Q4 2018 | +0.0% | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro